{"id":7123,"date":"2023-08-03T14:21:19","date_gmt":"2023-08-03T14:21:19","guid":{"rendered":"https:\/\/www.caltagmedsystems.co.uk\/information\/?p=7123"},"modified":"2025-04-17T12:21:35","modified_gmt":"2025-04-17T12:21:35","slug":"panoptosis-inflammatory-cell-death","status":"publish","type":"post","link":"https:\/\/www.caltagmedsystems.co.uk\/information\/panoptosis-inflammatory-cell-death\/","title":{"rendered":"PANoptosis – Inflammatory Cell Death"},"content":{"rendered":"\n
\"\"<\/a><\/figure>\n\n\n\n

Programmed cell death plays a crucial role in the development and host defence with an overlap and crosstalk between pyroptosis, apoptosis and necroptosis in the same cell population, leading to the concept of total cell death called PANoptosis. During PANoptosis activated by bacterial and viral triggers, inflammatory cell death occurs through the collective activation of pyroptosis, apoptosis and necroptosis, which can circumvent pathogen-mediated inhibition of individual death pathways. Molecules from the pyroptotic, apoptotic and necroptotic cell death pathways interact to form a single molecular complex termed the PANoptosome.<\/p>\n\n\n\n

Recent studies by the lab of Prof. Kanneganti (St. Jude Children’s Research Hospital, Memphis) identified the PANoptosome, a molecular platform triggering inflammatory cell death. PANoptotic stimuli (bacteria or virus) induce the formation of a PANoptosome complex with a number of pyroptotic, apoptotic and necroptotic molecules such as ZBP1, RIPK1, RIPK3, Caspase-1, Caspase-8, NLRP3, Asc and FADD under the regulation of ZBP1, TAK1 and Caspase-6. AIM2 and pyrin have been shown to be also members of the PANoptosome. The PANoptosome components have been implicated in a wide array of human diseases including autoinflammatory diseases, neurodegenerative diseases, cancer, microbial infections and metabolic diseases.<\/p>\n\n\n\n

Literature References:<\/h3>\n\n\n\n
    \n
  1. Identification of the PANoptosome: A Molecular Platform Triggering Pyroptosis, Apoptosis, and Necroptosis (PANoptosis): S. Christgen, et al.; Front. Cell.Infect. Microbiol. 10, 237 (2020)<\/a><\/li>\n\n\n\n
  2. The PANoptosome: A Deadly Protein Complex Driving Pyroptosis, Apoptosis, and Necroptosis (PANoptosis): P. Samir, et al.; Front. Cell Infect. Microbiol. 10, 238 (2020)<\/a><\/li>\n\n\n\n
  3. AIM2 forms a complex with pyrin and ZBP1 to drive PANoptosis and host defence: S.J. Lee, et al.; Nature 597, 415 (2021)<\/a><\/li>\n<\/ol>\n\n\n\n

    NEW PANoptosome Starter Sets<\/h2>\n\n\n\n
    Product Name<\/strong><\/td>PID<\/strong><\/td>PROTOCOL<\/strong><\/td><\/tr>
    PANoptosome Human Antibodies Starter Set<\/td>AG-44B-0012<\/a><\/td>The PANoptosome Human Antibodies Starter Set is an all-in-one solution to study the three key modes of programmed cell death, including pyroptosis, apoptosis and necroptosis using Western blotting application. This antibody starter set comprises our KO extract validated STANDARD antibodies against the key components of the NLRP3 inflammasome including NLRP3, Asc and Caspase-1, the cytosolic RNA\/DNA sensor ZBP1 and the apoptosis target caspase-8. These antibodies are used and published by the experts in inflammasome and cell death research. This economic starter set contains enough primary antibodies to perform at least 3 western blot experiments.<\/td><\/tr>
    PANoptosome Mouse Antibodies Starter Set<\/td>AG-44B-0013<\/a><\/td>The PANoptosome Human Antibodies Starter Set is an all-in-one solution to study the three key modes of programmed cell death, including pyroptosis, apoptosis and necroptosis using Western blotting application. This antibody starter set comprises our KO extract validated STANDARD antibodies against the key components of the NLRP3 inflammasome including NLRP3, Asc and Caspase-1, the cytosolic RNA\/DNA sensor ZBP1 and the apoptosis target caspase-8. These antibodies are used and published by experts in inflammasome and cell death research. This economic starter set contains enough primary antibodies to perform at least 3 western blot experiments.<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

    Most Trusted, Validated & Cited Antibodies for PANoptosis Research<\/h2>\n\n\n\n\n\n\n\t\n\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t
    Product Name<\/th>PID<\/th>Product Description<\/th>\n<\/tr>\n<\/thead>\n
    anti-ZBP1, mAb (Zippy-1)<\/td>AG-20B-0010<\/a><\/td>Recognizes human and mouse ZBP1.<\/td>\n<\/tr>\n
    anti-AIM2 (human), mAb (3B10)<\/td>AG-20B-0040<\/a><\/td>Recognizes human AIM2.<\/td>\n<\/tr>\n
    anti-Asc, pAb (AL177)<\/td>AG-25B-0006<\/a><\/td>Recognizes human and mouse Asc.<\/td>\n<\/tr>\n
    anti-Caspase-1 (p20) (mouse), mAb (Casper-1)<\/td>AG-20B-0042<\/a><\/td>Recognizes endogenous full-length and activated (p20 fragment) mouse caspase-1.<\/td>\n<\/tr>\n
    anti-Caspase-1 (p10) (mouse), mAb (Casper-2)<\/td>AG-20B-0044<\/a><\/td>Recognizes endogenous full-length and activated (p10 fragment) mouse caspase-1.<\/td>\n<\/tr>\n
    anti-Caspase-1 (p20) (human), mAb (Bally-1)<\/td>AG-20B-0048<\/a><\/td>Recognizes endogenous full-length and activated (p20 fragment) human caspase-1.<\/td>\n<\/tr>\n
    anti-Caspase-4 \/11 (p20), mAb (Flamy-1)<\/td>AG-20B-0060<\/a><\/td>Recognizes endogenous full-length protein and activated (p20) fragment of mouse and human caspase-4\/11. Does not detect human Caspase-5.<\/td>\n<\/tr>\n
    anti-Caspase-8 (human), mAb (C15)<\/td>AG-20B-0057<\/a><\/td>Recognizes the p18 subunit of human caspase-8.<\/td>\n<\/tr>\n
    anti-Caspase-8 (mouse), mAb (1G12)<\/td>AG-20T-0137<\/a><\/td>Recognizes full-length and the p18 cleaved fragment of mouse caspase-8.<\/td>\n<\/tr>\n
    anti-Caspase-8 (mouse), mAb (3B10)<\/td>AG-20T-0138<\/a><\/td>Recognizes full-length and the p18 cleaved fragment of mouse caspase-8.<\/td>\n<\/tr>\n
    anti-FLIP, mAb (Dave-2)<\/td>AG-20B-0005<\/a><\/td>Recognizes an epitope (aa 1-200) present in both short (FLIPS) and long (FLIPL) splice variants of human and mouse FLIP.<\/td>\n<\/tr>\n
    anti-FLIP (human), mAb (NF6)<\/td>AG-20B-0056<\/a><\/td>Recognizes short (FLIPS) and long (FLIPL) splice variants of human FLIP. This antibody recognizes an epitope in the N-terminal DED region (aa1-194).<\/td>\n<\/tr>\n
    anti-FADD (human), mAb (1C4)<\/td>AG-20B-0080<\/a><\/td>Recognizes the C-terminus of human FADD only in its unphosphorylated form.<\/td>\n<\/tr>\n
    anti-FADD (human), mAb (1C4) (Biotin)<\/td>AG-20B-0080B<\/a><\/td>Recognizes the C-terminus of human FADD only in its unphosphorylated form.<\/td>\n<\/tr>\n
    anti-NLRP3\/NALP3, mAb (Cryo-2)<\/td>AG-20B-0014<\/a><\/td>Recognizes mouse and human NLRP3\/NALP3.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n\n\n
    \n
    Read About PANoptosis on Adipogen’s Website<\/strong><\/a><\/div>\n\n\n\n
    View Inflammasomes Research Tools Flyer<\/strong><\/a><\/div>\n<\/div>\n\n\n\n
    \n\n\n\n

    Originally posted on adipogen.com\/panoptosis<\/a><\/p>\n\n\n\n

    Caltag Medsystems <\/a>is the distributor of Adipogen<\/a> products in the UK and Ireland. If you have any questions about these products, please contact<\/a> us<\/a>.<\/p>\n\n\n\n

    <\/div>\n\n\n\n

    <\/p>\n","protected":false},"excerpt":{"rendered":"

    PANoptosomes are involved in many diseases including autoinflammatory, metabolic & neurodegenerative diseases, cancer & microbial human infections.<\/p>\n","protected":false},"author":12,"featured_media":7952,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[132,1,622],"tags":[279,592],"class_list":["post-7123","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-antibodies","category-general-information","category-inflammation","tag-adipogen","tag-panoptosis"],"_links":{"self":[{"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/posts\/7123","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/users\/12"}],"replies":[{"embeddable":true,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/comments?post=7123"}],"version-history":[{"count":22,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/posts\/7123\/revisions"}],"predecessor-version":[{"id":12110,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/posts\/7123\/revisions\/12110"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/media\/7952"}],"wp:attachment":[{"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/media?parent=7123"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/categories?post=7123"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/tags?post=7123"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}